Alzheimer’s Initiative Widens Research Focus on Frontotemporal Degeneration With New $5M Commitment

Alzheimer’s Initiative Widens Research Focus on Frontotemporal Degeneration With New $5M Commitment
With a new $5-million commitment, the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator initiative is expanding its focus on frontotemporal degeneration, the most common form of dementia for individuals under 60. The funds come from a new research pledge of $2.5 million from The Association for Frontotemporal Degeneration (AFTD), which is being matched by a $2.5-million allocation of funds from the ADDF's Diagnostics Accelerator initiative, which was launched las
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *